Investor Relations

About Certara

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.

View company overview

News releases

View all
Jul 15, 2026

RADNOR, Pa., July 15, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2026 before market open on Tuesday, August 4 th, 2026.

Read more
Jul 07, 2026

New capabilities unify Certara's biosimulation software, products, datasets, and scientific expertise with AI-driven agents to deliver specialized insights for life sciences RADNOR, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug

Read more
Jun 17, 2026

Reaffirms 2026 Guidance RADNOR, Pa., June 17, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, announces that John Gallagher, Chief Financial Officer, has notified the Company of his intent to resign from his office effective as of the end

Read more